A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Incyte Corp stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 582,107 shares of INCY stock, worth $41.9 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
582,107
Previous 1,129,981 48.49%
Holding current value
$41.9 Million
Previous $68.5 Million 43.83%
% of portfolio
0.2%
Previous 0.31%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$57.33 - $68.61 $31.4 Million - $37.6 Million
-547,874 Reduced 48.49%
582,107 $38.5 Million
Q2 2024

Aug 09, 2024

SELL
$51.18 - $63.75 $2.94 Million - $3.66 Million
-57,430 Reduced 4.84%
1,129,981 $68.5 Million
Q1 2024

May 09, 2024

BUY
$56.55 - $66.59 $15.3 Million - $18 Million
271,048 Added 29.58%
1,187,411 $67.6 Million
Q4 2023

Feb 09, 2024

BUY
$52.16 - $64.19 $3.01 Million - $3.7 Million
57,633 Added 6.71%
916,363 $57.5 Million
Q3 2023

Nov 13, 2023

BUY
$57.77 - $65.93 $19.9 Million - $22.7 Million
345,036 Added 67.17%
858,730 $49.6 Million
Q2 2023

Aug 10, 2023

BUY
$60.95 - $75.51 $22.7 Million - $28.1 Million
372,289 Added 263.28%
513,694 $32 Million
Q1 2023

May 09, 2023

SELL
$70.23 - $86.01 $305,570 - $374,229
-4,351 Reduced 2.99%
141,405 $10.2 Million
Q4 2022

Feb 10, 2023

BUY
$67.18 - $84.11 $6.05 Million - $7.57 Million
90,030 Added 161.56%
145,756 $11.7 Million
Q3 2022

Nov 10, 2022

BUY
$66.18 - $82.86 $3.07 Million - $3.84 Million
46,366 Added 495.36%
55,726 $3.71 Million
Q2 2022

Aug 05, 2022

SELL
$66.18 - $83.18 $540,492 - $679,331
-8,167 Reduced 46.6%
9,360 $711,000
Q1 2022

May 12, 2022

SELL
$66.02 - $79.71 $13.8 Million - $16.7 Million
-209,002 Reduced 92.26%
17,527 $1.39 Million
Q4 2021

Feb 10, 2022

BUY
$63.34 - $74.11 $8.76 Million - $10.2 Million
138,269 Added 156.66%
226,529 $16.6 Million
Q3 2021

Nov 12, 2021

BUY
$68.67 - $84.02 $222,696 - $272,476
3,243 Added 3.81%
88,260 $6.07 Million
Q2 2021

Aug 12, 2021

BUY
$79.87 - $87.53 $1.53 Million - $1.68 Million
19,147 Added 29.07%
85,017 $7.15 Million
Q1 2021

May 13, 2021

BUY
$76.02 - $100.5 $4.1 Million - $5.42 Million
53,898 Added 450.2%
65,870 $5.35 Million
Q4 2020

Feb 16, 2021

BUY
$80.74 - $97.7 $55,226 - $66,826
684 Added 6.06%
11,972 $1.04 Million
Q3 2020

Nov 12, 2020

BUY
$85.07 - $109.69 $214,461 - $276,528
2,521 Added 28.76%
11,288 $1.01 Million
Q2 2020

Aug 13, 2020

BUY
$74.18 - $108.93 $161,860 - $237,685
2,182 Added 33.14%
8,767 $912,000
Q1 2020

May 13, 2020

SELL
$63.18 - $85.97 $40,435 - $55,020
-640 Reduced 8.86%
6,585 $0
Q4 2019

Feb 12, 2020

SELL
$73.04 - $95.72 $887,436 - $1.16 Million
-12,150 Reduced 62.71%
7,225 $631,000
Q3 2019

Nov 13, 2019

BUY
$72.82 - $86.52 $944,839 - $1.12 Million
12,975 Added 202.73%
19,375 $1.44 Million
Q2 2019

Aug 07, 2019

BUY
$73.52 - $88.7 $248,130 - $299,362
3,375 Added 111.57%
6,400 $544,000
Q1 2019

May 08, 2019

BUY
$63.56 - $88.17 $192,269 - $266,714
3,025 New
3,025 $260,000
Q3 2018

Nov 13, 2018

SELL
$61.75 - $74.23 $748,780 - $900,112
-12,126 Closed
0 $0
Q2 2018

Aug 02, 2018

BUY
$60.85 - $83.98 $342,342 - $472,471
5,626 Added 86.55%
12,126 $812,000
Q1 2018

May 14, 2018

SELL
$83.06 - $100.98 $257,486 - $313,038
-3,100 Reduced 32.29%
6,500 $542,000
Q4 2017

Feb 09, 2018

BUY
$93.56 - $116.6 $39,763 - $49,555
425 Added 4.63%
9,600 $909,000
Q3 2017

Nov 14, 2017

BUY
$109.15 - $138.27 $139,166 - $176,294
1,275 Added 16.14%
9,175 $1.07 Million
Q2 2017

Aug 14, 2017

BUY
N/A
7,900
7,900 $995,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.